



AMITY UNIVERSITY

Established vide Maharashtra Act No. 13 of 2014, of Government of Maharashtra, and recognised under Section 2 (f) of UGC ACT 1956.

MEMORANDUM OF UNDERSTANDING

BETWEEN

**AMITY UNIVERSITY, MAHARASHTRA
MAHARASHTRA – 410206.**

and

**GOVERNMENT DENTAL COLLEGE & HOSPITAL,
ST. GEORGE'S HOSPITAL COMPOUND, FORT
MUMBAI, MAHARASHTRA-400001.**

AMITY UNIVERSITY, MAHARASHTRA (hereinafter referred to as "AUM"), represented by its Registrar Dr. H. Vyas, FIRST PARTY.

and

GOVERNMENT DENTAL COLLEGE & HOSPITAL, MUMBAI, MAHARASHTRA (hereinafter referred to as "GDCH, Mumbai"), represented by its Dean Dr. Dimple Padawe, SECOND PARTY.

This Memorandum of Understanding (hereinafter referred to as "MoU") is executed on this day of 2023 (Dated: 20.4.2023) between AUM and GDCH, Mumbai.

This MoU sets out an understanding for co-operation to enhance academic and research opportunities for faculties and students to collect the human oral samples and clinical survey of patients with associated of various disease paradigms.

AUM, Maharashtra and GDCH, Mumbai are both legal entities fully empowered to conduct their own affairs.

The Parties have agreed to enter into this MoU in order to record their wish to explore the potential for co-operation in the field and this MoU records only their current intentions and does not give rise to legal relations.

The Parties wish to co-operate to explore the potential to work together in the following areas:

- i. Developments in learning and teaching quality.
- ii. Developing and sharing of publications and materials of common interest.
- iii. Research collaboration.
- iv. Externship posting of Postgraduate, Doctorate Research Scholars and Teaching faculty of AUM for undergoing one week exchange programme at GDCH, Mumbai, Maharashtra.
- v. Externship posting for Postgraduate students, Doctorate and Teaching faculty GDCH, Mumbai, Maharashtra for undergoing one week exchange programme. at AUM.



Page 1 of 2

The duration of this MoU shall come in to force from the date of its signature and shall remain valid for a period of two years. It may be terminated before it expires by either party giving not less than one-month notice in writing to the other.

The purpose of this MoU is to facilitate the interaction between Postgraduate students, Doctorate Research Scholars and Teaching faculty members of both parties to enhance the outcome of training and academic and research.

This MoU will be purely for academic purpose including sharing of knowledge through seminars/ workshops/ symposia and publications but excluding any financial transaction.

In witness whereof the undersigned, duly authorized thereto, have signed this MOU on this day,

<p>Amity University, Maharashtra</p>   <p>Name: Dr. Hira S. Vyas, Registrar, Amity University Mumbai-Pune Expressway, Bhatan, Post-Somathne, Panvel, Mumbai, Maharashtra- 410206</p> <p>Date: <u>20.4.2023</u></p> <p>Place: <u>MUMBAI</u></p> <p>Witnessed by:</p>  <p>Dr. P Suprasanna Dean Research (i/C), Amity University HOI, Amity Institute of Biotechnology (AIB) Mumbai-Pune Expressway, Bhatan, Post-Somathne, Panvel, Mumbai, Maharashtra- 410206</p> <p>Signed: </p> <p>Date: <u>20.4.2023</u></p>	<p>Government Dental College & Hospital.</p>  <p>Name: Dr. Dimple D. D. D., Dean, GDCH, Mumbai Government Dental College & Hospital St. George Hospital Complex, Fort Mumbai, Maharashtra- 400001</p> <p>Date: <u>20.4.2023</u></p> <p>Place: <u>MUMBAI</u></p> <p>Witnessed by:</p>  <p>Dr. Dhalkari C Digambarrao Prof & HOD Dept. of Periodontology Government Dental College & Hospital St. George Hospital Complex, Fort Mumbai, Maharashtra- 400001</p>  <p>Dr. C.D. Dhalkari Professor & Head M.D.S. Dept. of Periodontology Govt. Dental College & Hospital Mumbai-400001</p> <p>Signed: </p> <p>Date: <u>20.4.2023</u></p>
---	---

MEMORANDUM OF UNDERSTANDING BETWEEN

AMITY UNIVERSITY, MAHARASHTRA
MAHARASHTRA – 410206.

and

miBIOME THERAPEUTICS LLP
MUMBAI, MAHARASHTRA-400102.

AMITY UNIVERSITY, MAHARASHTRA (hereinafter referred to as “**AUM**”), represented by its Registrar Dr. H. Vyas, **FIRST PARTY**.

and

miBIOME THERAPEUTICS LLP (hereinafter referred to as “**miBiome Therapeutics LLP**”), Mumbai, Maharashtra, represented by its Co-Founder & Managing Partner Dr. Gautam Das, **SECOND PARTY**.

This Memorandum of Understanding (hereinafter referred to as “**MoU**”) is executed on this **day of 2023** (Dated: 13-06-2023) between **AUM and miBiome Therapeutics LLP**.

This **MoU** sets down the mutually agreed broad framework for joint research and academic activities in various fields of interest. It also incorporates the modalities for collaboration. For the purpose of this MoU, AUM and miBiome Therapeutics LLP shall be collectively referred to as “**parties**” and the term “**party**” refers to either of them as the context permits.

PREAMBLE

AUM is a reputed university under the Act of Maharashtra and further to its academic deliveries, it is also involved in conducting basic and applied research having impact on human health and cutting-edge translational research in diversified fields. The University has 6 centers of excellences in the area of Drug Delivery, Genomics and Proteomics, Translational Research, Astrobiology, Nuclear Bioscience and Nanotechnology.

miBiome Therapeutics LLP, is an advanced science and deep tech start-up empowering healthcare and science through the power of genomics for past 3.5 years. The institutions share a vision with a mission to democratize #GenomicsForAll by decoding life through deep technology in every sector. The institution has two verticals, CoEVIDD- Centre of Excellence in Viral & Infectious Diseases Diagnostics (COVID-UNIQSEQ, MTB-SEQ, TB-DRUGSEQ, AMR-SEQ, Sapiens-SEQ, miRESPIRATORYBiome), and Clinical Genomics (i.e., miInfectionBiome, miResistantBiome, miCancerBiome, miReproductiveBiome, miInheritedBiome and miImmuneBiome) focusing on

various aspects of High-throughput Sequencing techniques in various domains of genomics i.e., DNA Based, RNA Based, Metagenomics and Epigenetics using modern technology such as Automated DNA extraction system (Qiagen), Qubit, Agilent TapeStation system, Illumina NGS, Oxford Nanopore NGS and Thermo Real Time PCR.

The activities of both the parties are in several ways complementary to each other. It is therefore felt that initiating joint collaborative research programs and training would be of considerable mutual interest & benefit.

PURPOSE

Both the parties desire to implement various collaborative activities, in areas of mutual interest, which would address multidisciplinary scientific and technological issues of national relevance. For this purpose, both parties are desirous of entering into a **MoU**. Consistent with the goals and purpose of the collaboration, **AUM** and **miBiome Therapeutics LLP** propose to initiate joint multidisciplinary research, inter-alia the areas given below:

ARTICLE - 1: Joint Research Programs and collaborations.

The major research work will be focused on human microbiome associated with different disease conditions. Furthermore, the research activities will be initiated on other areas of plant, animal and microbial genomics based on mutual interest of both parties.

Where:

- a) Faculty and researchers from both parties can collaborate on projects based on mutual interests as part of their respective intramural research programs. The collaborating faculty can avail the facilities of both institutions by paying appropriate charges from the budget of intramural research programs.
- b) Faculty from both parties can explore possibilities of joint twining research programs in interdisciplinary areas of specialization of high relevance to both parties.
- c) Both parties can be involved in joint submission of projects to different National and International funding agencies for extramural funding.
- d) miBiome Therapeutics LLP can provide access to various high end sophisticated equipment for research related activities to the designated faculty of AUM on mutually agreeable terms and conditions.

ARTICLE - 2: Joint Academic Programs and Workshops

- a) miBiome Therapeutics LLP employee can enroll for part time PhD program at AUM after fulfilling eligibility criteria and applicable fees requirements.
- b) Exchange of faculty and researcher members: Planning and handling of courses, organization of seminars, workshops and conferences including the exchange of mutual experiences in research and industrial practice can be envisaged. During exchange visits, the faculty should take prior approvals from the respective competent authorities.
- c) Students from AUM can undertake their internship and dissertations at miBiome Therapeutics LLP.
- d) Special lectures by miBiome Therapeutics LLP scientists in the area of Drug Delivery, Genomics and Proteomics, Translational Research, Nuclear Bioscience and Nanotechnology can be arranged for UG and PG program of AUM.

- e) Capacity building of the students & staff of either party in the areas of common interest. Short-term continuing education programs, seminars, conferences, certificate courses, and workshops on topics of mutual interest can be organized jointly involving members from both the institutions.
- f) Use of major equipment and services at a subsidized payment and when required and mutually agreed by both the parties.
- g) Exchange in Research: Exchange of information and co-operation in research and developments including joint publications and reports.

ARTICLE - 3: Intellectual property rights

- a) Information on research results and scientific materials (data, reports, articles, books, technical documents & related literature) on the collaborative programs between both the parties will be exchanged freely keeping in mind the mutually agreed provision of Intellectual Property Rights.
- b) Intellectual property (IP) solely conceived and/or developed by AUM during the course of this Agreement shall be owned by AUM. Intellectual property (IP) solely conceived and/or developed by miBiome Therapeutics LLP during the course of this Agreement shall be owned by miBiome Therapeutics LLP.
- c) Intellectual property (IP) conceived and/or developed jointly during the course of this Agreement shall be jointly owned by AUM and miBiome Therapeutics LLP.
- d) Each party may use such jointly developed IP for research and scholarly purposes or for commercial purposes with mutual consent & on mutually agreed commercial terms. IPs developed solely by either party during the tenure of this MOU shall not require any mutual consent for commercial use by the other party.
- e) Both Parties agree to collaborate towards the protection, if appropriate, and application of such intellectual property (IP) for commercial or other purposes on mutually acceptable terms to be negotiated in good faith between the parties.
- f) Both parties reserve the rights to jointly commercialize and assign any jointly developed intellectual property (IP) to any third party with prior consent of each other & on mutually agreed commercial terms.

ARTICLE - 4: Financial Clause

Notwithstanding anything contained in the provisions of accepting Article - 4 of the **MoU**, either party or both parties together shall have the right to seek additional funds for and/or to cooperate with any agency/institute for any of the projects covered under the **MoU** through mutual consent & after prior intimation. ***There will be no financial obligations on both the parties under this agreement.***

ARTICLE - 5: Legal Relationship

This MoU shall be construed as a statement of purpose to promote a genuine and mutually beneficial collaboration between the parties.

A detailed agreement shall be further executed from case-to-case basis and wherever necessary as per joint activities undertaken, mentioned within article 1, article 2 and article 3 of this contract.

ARTICLE - 6: Amendment of MoU

Any article of the **MoU** may be modified or changed by mutual agreement of both the parties hereto in writing. The modifications/changes shall be effective from the date on which they are modified /extended in writing unless otherwise agreed to.

ARTICLE - 7: Dispute Settlement

All disagreements/differences of opinion/disputes regarding the interpretation of the provisions of

this MoU shall be resolved by mutual consultation by the signatories to this MoU. However, in case, the dispute persists, the matter shall be referred to and amicably resolved by arbitration to be conducted by the sole arbitrator to be nominated jointly by Head of both the institutions. The award of the arbitrator shall be final and binding on the parties.

ARTICLE - 8: Monitoring & Coordination




The mentioned work will be coordinated by **Dr. P Suprasanna, Dean Research (i/C) HOI, Amity Institute of Biotechnology, AUM** (on behalf of AUM) and **Dr. Gautam Das, Co-Founder & Managing Partner, miBiome Therapeutics LLP** (on behalf of miBiome Therapeutics LLP).

ARTICLE - 9: Validity and Termination of MoU

This MoU shall come into force from the date of its signatures and shall remain valid for a period of 3 years. This MoU may be modified, renewed or extended with mutual written consent of both parties. Either party may terminate this MoU by giving three (3) months' notice in writing to the other party.

In witness whereof the undersigned, duly authorized thereto, have signed this MOU on this day,

13/06/23

Amity University, Maharashtra  13.06.2023	miBiome Therapeutics LLP  13.06.2023
Name: Prof. (Dr.) A.W. Santhosh Kumar, Vice Chancellor, Amity University Maharashtra, Mumbai-Pune Expressway, Bhatnagar, Post-Somathane, Panvel, Mumbai, Maharashtra- 410206	Name: Dr. Gautam Das, Co-Founder & Managing Partner, miBiome Therapeutics LLP Flexcel Park, C Wing, Swami Nivekananda Rd, Momin Nagar, Jogeshwari West, Mumbai, Maharashtra-400102
Date: <u>13/06/2023</u>	Date: <u>13/06/23</u>
Place: <u>Jogeshwari</u>	Place: <u>Jogeshwari</u>
Witnessed by: Full Name: <u>Dr. P. Suprasanna</u> Designation: <u>Dean Research</u> Sign:  Date: <u>13/06/23</u>	Witnessed by: Full Name: <u>NANDINI DASGUPTA</u> Designation: <u>Science Team head</u> Sign: <u>Nandini Dasgupta</u> Date: <u>13.06.2023</u>





MEMORANDUM OF UNDERSTANDING

This Memorandum of Understanding (hereinafter referred to as “MoU”) is executed on this 12th April 2023 **by and between**

AMITY UNIVERSITY, MUMBAI, MAHARASHTRA (hereinafter referred to as “AUM”), represented by its Registrar Dr. H. Vyas, of the **First Part;**

And

LIFECCELL INTERNATIONAL PRIVATE LIMITED, a private limited company incorporated under the Companies Act, 1956 with corporate identification number U85196TN2004PTC053577 and having its registered office at No.16, Vijayaraghava Road, I Lane, T Nagar, Chennai, Tamil Nadu 600017, India (hereinafter referred to as “LifeCell”, which expression shall, unless it be repugnant to the context or meaning thereof, be deemed to mean and include its successors, Affiliates, nominees and permitted assigns), of the **Second Part;**

For the purpose of this MoU, **AUM** and **LifeCell** shall be collectively referred to as “**parties**” and the term “**party**” refers to either of them as the context so permits.

This **MoU** sets down the mutually agreed broad framework for joint research and academic activities in various fields of interests. It also incorporates the modalities for collaboration.

PREAMBLE

AUM is a reputed university under the Act of Maharashtra state Government and further to its academic deliveries, it is also involved in conducting basic and applied research having impact on human health and cutting edge translational research in diversified fields. The University in houses 5 centers of excellences in the area of Astrobiology, Computational Biology, Translational Research, Drug Delivery and Development, Genomics, Proteomics and Nanotechnology.

LifeCell International Private Limited was established in the year 2004 as Company in the business of (a) collecting, processing, testing, preserving, and/or distribution of human cells and tissues; (b) skincare ingredients and products developed basis regenerative science; and (c) establishing and operating diagnostic laboratories and service centers in India.

The activities of both the parties are in several ways complementary to each other. It is therefore felt that initiating joint collaborative research programs and training would be of considerable mutual interest & benefit.

PURPOSE

Both the parties desire to implement various collaborative activities, in areas of mutual interest, which would address multidisciplinary scientific and technological issues of national relevance. For this purpose, both parties are desirous of entering into a **MoU**. Consistent with the goals and purpose of the collaboration, **LifeCell** and **AUM** propose to initiate joint multidisciplinary research, inter-alia the areas given below:

ARTICLE - 1: Joint Research Programs and collaborations

The major fields of work at AUM will be Genomics & Proteomics, Cancer & Stem cell biology, Plant and Animal Biotechnology, Microbial & Environmental Biotechnology.

Where

- a) Faculty from both parties can collaborate on projects based on mutual interests as part of their respective intramural research programs. The collaborating faculty can avail the facilities of both institutions by paying appropriate charges from the budget of intramural research programs.
- b) Faculty from both parties can explore possibilities of joint twining research programs in interdisciplinary areas of specialization of high relevance to both parties.
- c) Both parties can be involved in joint submission of projects to different funding agencies for extramural funding.
- d) **LifeCell** can provide access to various high end sophisticated equipment for research related activities and give remote access of its servers to the designated faculty of **AUM** on mutually agreeable terms and conditions.

ARTICLE - 2: Joint Academic Programs and Workshops

- a) Exchange of Faculty members: Planning and handling of courses, organization of seminars, workshops and conferences including the exchange of mutual experiences in research and industrial practice can be envisaged. During exchange visits, the faculty should take prior approvals from the respective competent authorities.
- b) Capacity building of the students & staff of either party in the areas of common interest. Short-term continuing education programs, seminars, conferences, certificate courses, and workshops on topics of mutual interest can be organized jointly involving faculty members from both the institutions.
- c) Use of major equipment and services at a subsidized payment as designated by the Director, **LifeCell** as and when required and mutually agreed by both the parties.

ARTICLE - 3: Joint Supervision and Exchange of Students

- a) For PhD Students' Project: A PhD student from **AUM** can be co-supervised by faculty member(s) from **LifeCell**. Faculty members from **AUM** can act as doctoral committee members of **LifeCell**.

- b) Both parties will facilitate the visit of their respective faculty and students to engage in scientific research and training. After due permission, students from either party can work in the other institute and use the facilities for collaborative projects with the approval of the concerned departments/competent authority of the other institute. Either party will provide accommodation of the visiting students at minimal charges possible.
- c) Exchange in Research: Exchange of information and co-operation in research and developments including exchange of publication and reports.

ARTICLE - 4: Intellectual property rights

- a) Information on research results and scientific materials (data, reports, articles, books, technical documents & related literature) on the collaborative programs between both the parties will be exchanged freely keeping in mind the mutually agreed provision of Intellectual Property Rights.
- b) Intellectual property (IP) solely conceived and/or developed by **AUM** during the course of this Agreement shall be owned by **AUM**. Intellectual property (IP) solely conceived and/or developed by **LifeCell** during the course of this Agreement shall be owned by **LifeCell**.
- c) Intellectual property (IP) conceived and/or developed jointly during the course of this Agreement shall be jointly owned by **AUM** and **LifeCell**.
- d) Each party may use such IP for research and scholarly purposes or for commercial purposes with mutual consent.
- e) Both Parties agree to collaborate towards the protection, if appropriate, and application of such intellectual property (IP) for commercial or other purposes on mutually acceptable terms to be negotiated in good faith between the parties.
- f) Both parties reserve the rights to commercialize, use and assign the intellectual property (IP) to any third party that are conceived and/or developed as per sub-clause c) under Article 4 with prior consent of each other.

ARTICLE - 5: Financial Clause

Notwithstanding anything contained in the provisions of accepting Article - 5 of the **MoU**, either party or both parties together shall have the right to seek additional funds for and/or to cooperate with any agency/institute for any of the projects covered under this **MoU** through mutual consent & after prior intimation. *There will be no financial obligations on both the parties under this agreement.*

ARTICLE - 6: Legal Relationship

This **MoU** shall be construed as a statement of purpose to promote a genuine and mutually beneficial collaboration between the parties.

ARTICLE - 7: Amendment of MoU

Any article of the **MoU** may be modified or changed by mutual agreement of the parties hereto in writing. The modifications/changes shall be effective from the date on which they are modified /extended in writing unless otherwise agreed to.

ARTICLE - 8: Dispute Settlement

All disagreements/differences of opinion/disputes regarding the interpretation of the provisions of

this MoU shall be resolved by mutual consultation by the signatories to this MoU. However, in case, the dispute persists, the matter shall be referred to and amicably resolved by arbitration to be conducted by the sole arbitrator to be nominated jointly by Directors of both the Parties. The award of the arbitrator shall be final and binding on the parties. The arbitration proceedings will be conducted in accordance with the Indian Arbitration & Conciliation Act, 1996 and Venue of the Arbitration Centre will be Chennai.

ARTICLE - 9: Monitoring & Coordination

Both parties shall establish a Co-ordination Committee which will ensure the smooth functioning of the research and academic programs. The Dean- Research, AUM will be Chairperson, and Director LifeCell will be Convener of the Coordination Committee, which will comprise representatives of both the parties.

ARTICLE - 10: Validity and Termination of MoU

This MoU shall come into force from the date of its signatures and shall remain valid for a period of 5 years. This MoU may be modified, renewed or extended with mutual written consent of both parties. Either party may terminate this MoU by giving three (3) months' notice in writing to the other party.

ARTICLE – 12: Miscellaneous

A) Confidentiality

For the purpose of this clause, Confidential information means any information used by AUM & LifeCell to develop trade secrets, including documents, reports, data, models, designs, financial plans, procedures, software, formula, patents, patent applications or general know-how that was communicated verbally, electronically or in print.

Trade Secrets mean information possessed and developed by AUM and LifeCell that holds inherent economic value because it is not known by the general public or by either party's competitors. This may include but is not limited to formulas, programs, data, techniques, processes, patterns, or other information as deemed by the parties to this MoU.

Both AUM and LifeCell agrees to keep all Confidential Information and Trade Secrets belonging AUM and LifeCell in the strictest of confidence and shall not disclose Confidential Information or Trade Secrets to any unauthorized third party. Failure to keep Confidential Information and Trade Secrets result in legal action by the aggrieved party and other party will be required to pay any and all of the aggrieved party's attorney fees.

This Confidentiality Clause remains in full force and effect up to 5 years even after termination of the Agreement by its natural termination or the early termination by either party.

B) Indemnity

AUM and LifeCell agree to indemnify and hold harmless to each other, its respective affiliates, officers, agents, employees, and permitted successors and assigns against any and all claims, losses, damages, liabilities, penalties, punitive damages, expenses, reasonable legal fees and costs of any kind or amount whatsoever, which result from the negligence of or breach of this MoU by the indemnifying party, its respective successors and assignees that occurs in connection with this MoU.

This section remains in full force and effect even after termination of the Agreement by its natural termination or the early termination by either party.

C) Governing Law & Jurisdiction

This Agreement shall be construed and enforced solely pursuant to the laws of India, without giving effect to the principles of conflicts of laws thereof and the parties to this MoU shall be subject to the sole and exclusive jurisdiction of the High Courts and District Courts located in Chennai (India). The Parties agree that the foregoing governing law, jurisdiction and forum selections have been concluded as a result of arms-length negotiations and are not burdensome to either Party. Notwithstanding the foregoing, any court with competent jurisdiction may enforce the judgment and ruling of the High Court and District Courts located in Chennai.

D) Force Majeure

In the event where AUM and LifeCell are unable to perform the objective in pursuant to this MoU due to causes beyond the control of both the parties, including, but not limited to: acts of God; war; acts of the government; fires; floods; epidemics; quarantine restrictions; Pandemic; strikes, riots, labor disputes or work stoppages; transportation contingency; and freight embargoes; other catastrophes or any similar occurrences beyond parties reasonable control, neither AUM nor LifeCell shall be considered in breach of this MOU and shall not be held liable for the same.

E) Assignment

Neither AUM nor LifeCell assign this MoU or any rights or obligations under this MoU to any person or entity without the prior written consent of the other party. Any assignment in violation of this provision is null and void.

F) Severability

If a court of competent jurisdiction finds that any section, paragraph, clause, or provision of this Agreement is invalid or otherwise unenforceable, the remaining clauses in this Agreement shall remain in full force and effect.

G) Entire MOU

This MoU constitutes the entire MoU and understanding between the parties as to the subject matter hereof and supersedes all prior discussions, agreements and undertakings of every kind and nature between them, whether written or oral, with respect to such subject matter.

H) Amendment and Modification

In the event that the Parties to this MoU desire to change, add, or otherwise modify any terms, the same can be executed with the written consent of both AUM and LifeCell.


I) Waiver

The failure by either Party to exercise any right, power, or privilege under the terms of this MoU will not be construed as a waiver of any subsequent or future exercise of that right, power or privilege or the exercise of any other right, power, or privilege.

J) Counterparts

This MoU may be executed in one or more counterparts, each of which will be deemed to be an original, but all of which together will constitute one and the same instrument, without necessity of production of the others. An executed signature page delivered via facsimile transmission or electronic signature shall be deemed as effective as an original executed signature page.

In witness whereof the undersigned, duly authorized thereto, have signed this MoU on 12th April 2023.

<p>Amity University- Mumbai</p>   <p>Name: Dr. Hira S. Vyas, Registrar, Amity University Mumbai-Pune Expressway, Bhatan, Post-Somathne, Panvel, Mumbai, Maharashtra- 410206</p> <p>Date: <u>12/04/23</u></p> <p>Place: <u>Panvel</u></p> <p><i>Witnessed by:</i></p>  <p>Dr. P Suprasanna Dean Research (i/C), Amity University HOI, Amity Institute of Biotechnology (AIB) Mumbai-Pune Expressway, Bhatan, Post-Somathne, Panvel, Mumbai, Maharashtra- 410206</p> <p>Signed: _____</p> <p>Date: <u>12/04/23</u></p>	<p>LifeCell International Private Limited</p>   <p>Name: Mr. Mayur Abhaya Managing Director No.16, Vijayaraghavar Road, I Lane T. Nagar, Chennai -600017</p> <p>Date: _____</p> <p>Place: _____</p> <p><i>Witnessed by:</i></p>  <p>Name: Dr. Prakash Gambhir, MD Chief Medical Scientist, LifeCell No.16, Vijayaraghavar Road, I Lane T. Nagar, Chennai -600017</p> <p>Signed: _____</p> <p>Date: _____</p>
---	--

Notary